Home Stock

Stock Research: AbbVie

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

AbbVie

NYQ:ABBV US00287Y1091
53
  • Value
    34
  • Growth
    78
  • Safety
    Safety
    30
  • Combined
    49
  • Sentiment
    61
  • 360° View
    360° View
    53
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

AbbVie Inc. is a global biopharmaceutical company focused on research, development, manufacturing, and commercialization of medicines and therapies. Key areas include Immunology, Oncology, Aesthetics, Neuroscience, and Eye Care. In the last fiscal year, the company had a market cap of $329,240 million, profits of $39,430 million, revenue of $56,334 million, and 55000 employees.

more

ANALYSIS: With an Obermatt 360° View of 53 (better than 53% compared with alternatives), overall professional sentiment and financial characteristics for the stock AbbVie are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for AbbVie. The consolidated Growth Rank has a good rank of 78, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 78% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 61, which means that professional investors are more optimistic about the stock than for 61% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 34, which means that the share price of AbbVie is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 66% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 30, which means that the company has a financing structure that is riskier than those of 70% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Price vs. Book (P/B)
Weakest Rank Dividend Yield
Country USA
Industry Biotechnology
Size XX-Large
Website abbvie.com
Index
D.J. US Health Care
S&P 500
AbbVie stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
34 72 n/a n/a
Growth
78 35 n/a n/a
Safety
Safety
30 36 n/a n/a
Sentiment
61 96 n/a n/a
360° View
360° View
53 75 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
11 35 n/a n/a
Opinions Change
77 70 n/a n/a
Pro Holdings
n/a 94 n/a n/a
Market Pulse
86 85 n/a n/a
Sentiment
61 96 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
34 72 n/a n/a
Growth
78 35 n/a n/a
Safety Safety
30 36 n/a n/a
Combined
49 43 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
48 28 n/a n/a
Price vs. Earnings (P/E)
14 61 n/a n/a
Price vs. Book (P/B)
3 1 n/a n/a
Dividend Yield
100 100 n/a n/a
Value
34 72 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
51 35 n/a n/a
Profit Growth
100 53 n/a n/a
Capital Growth
69 33 n/a n/a
Stock Returns
28 59 n/a n/a
Growth
78 35 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
12 9 n/a n/a
Refinancing
35 5 n/a n/a
Liquidity
79 92 n/a n/a
Safety Safety
30 36 n/a n/a

Similar Stocks

Discover high‑ranked alternatives to AbbVie and broaden your portfolio horizons.

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Resideo Technologies

NYQ:REZI
Country: USA
Industry: Building Products
Size: Large
Full Stock Analysis

Peabody Energy

NYQ:BTU
Country: USA
Industry: Coal & Consumable Fuels
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews